# üî¨ Tezepelumab Path Analysis Report

*Generated: 2025-12-07 14:00:25*

## 1. Drug Profile

| Property | Value |
|----------|-------|
| **Drug ID** | DB15090 |
| **Drug Name** | Tezepelumab |
| **Type** | drug |

## 2. Path Statistics

| Metric | Value |
|--------|-------|
| **Total Paths** | 100 |
| **Unique Diseases** | 87 |
| **Mean Attention** | 0.6419 |
| **Std Attention** | 0.0607 |
| **Min Attention** | 0.5000 |
| **Max Attention** | 0.7696 |

### Paths by Hop Count

| Hops | Count |
|------|-------|
| 2 | 400 |
| 3 | 400 |
| 4 | 400 |
| 5 | 400 |

## 3. Path Type Summary

| Path Type | Count | Description |
|-----------|-------|-------------|
| Drug Similarity | 100 | Paths through similar drugs |
| Protein Target | 0 | Paths through protein targets |
| Pathway | 0 | Paths through biological pathways |
| Biological Process | 0 | Paths through biological processes |
| Other | 0 | Other connection types |

### Key Similar Drugs

| Similar Drug | Max Attention | # Diseases |
|--------------|---------------|------------|
| Chlorotrianisene | 0.8739 | 73 |
| Mestranol | 0.8352 | 25 |
| Tibolone | 0.8214 | 2 |

## 4. Top 20 Paths (by Combined Score)

### Path #1: ovarian carcinosarcoma

**Path:**
```
[Tezepelumab] --(0.874)--> [Chlorotrianisene] --(0.540)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 2 |
| Avg Attention | 0.7071 |
| Combined Score | 0.5000 |
| Confidence | ‚≠ê‚≠ê‚≠ê‚≠ê‚≠ê Very High |

**Node Types:** `drug` ‚Üí `drug` ‚Üí `disease`

**Interpretation:**

**Drug similarity path**: Tezepelumab is similar to Chlorotrianisene, which is associated with ovarian carcinosarcoma. This suggests shared therapeutic mechanisms.

---

### Path #2: uterine corpus leiomyoma

**Path:**
```
[Tezepelumab] --(0.874)--> [Chlorotrianisene] --(0.538)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 2 |
| Avg Attention | 0.7060 |
| Combined Score | 0.4992 |
| Confidence | ‚≠ê‚≠ê‚≠ê‚≠ê‚≠ê Very High |

**Node Types:** `drug` ‚Üí `drug` ‚Üí `disease`

**Interpretation:**

**Drug similarity path**: Tezepelumab is similar to Chlorotrianisene, which is associated with uterine corpus leiomyoma. This suggests shared therapeutic mechanisms.

---

### Path #3: maligant granulosa cell tumor of ovary

**Path:**
```
[Tezepelumab] --(0.874)--> [Chlorotrianisene] --(0.537)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 2 |
| Avg Attention | 0.7056 |
| Combined Score | 0.4989 |
| Confidence | ‚≠ê‚≠ê‚≠ê‚≠ê‚≠ê Very High |

**Node Types:** `drug` ‚Üí `drug` ‚Üí `disease`

**Interpretation:**

**Drug similarity path**: Tezepelumab is similar to Chlorotrianisene, which is associated with maligant granulosa cell tumor of ovary. This suggests shared therapeutic mechanisms.

---

### Path #4: cerebral infarction

**Path:**
```
[Tezepelumab] --(0.874)--> [Chlorotrianisene] --(0.537)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 2 |
| Avg Attention | 0.7054 |
| Combined Score | 0.4988 |
| Confidence | ‚≠ê‚≠ê‚≠ê‚≠ê‚≠ê Very High |

**Node Types:** `drug` ‚Üí `drug` ‚Üí `disease`

**Interpretation:**

**Drug similarity path**: Tezepelumab is similar to Chlorotrianisene, which is associated with cerebral infarction. This suggests shared therapeutic mechanisms.

---

### Path #5: intrinsic asthma

**Path:**
```
[Tezepelumab] --(0.874)--> [Chlorotrianisene] --(0.536)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 2 |
| Avg Attention | 0.7047 |
| Combined Score | 0.4983 |
| Confidence | ‚≠ê‚≠ê‚≠ê‚≠ê‚≠ê Very High |

**Node Types:** `drug` ‚Üí `drug` ‚Üí `disease`

**Interpretation:**

**Drug similarity path**: Tezepelumab is similar to Chlorotrianisene, which is associated with intrinsic asthma. This suggests shared therapeutic mechanisms.

---

### Path #6: endometrium neoplasm

**Path:**
```
[Tezepelumab] --(0.874)--> [Chlorotrianisene] --(0.535)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 2 |
| Avg Attention | 0.7046 |
| Combined Score | 0.4982 |
| Confidence | ‚≠ê‚≠ê‚≠ê‚≠ê‚≠ê Very High |

**Node Types:** `drug` ‚Üí `drug` ‚Üí `disease`

**Interpretation:**

**Drug similarity path**: Tezepelumab is similar to Chlorotrianisene, which is associated with endometrium neoplasm. This suggests shared therapeutic mechanisms.

---

### Path #7: migraine with or without aura, susceptibility to

**Path:**
```
[Tezepelumab] --(0.874)--> [Chlorotrianisene] --(0.535)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 2 |
| Avg Attention | 0.7045 |
| Combined Score | 0.4981 |
| Confidence | ‚≠ê‚≠ê‚≠ê‚≠ê‚≠ê Very High |

**Node Types:** `drug` ‚Üí `drug` ‚Üí `disease`

**Interpretation:**

**Drug similarity path**: Tezepelumab is similar to Chlorotrianisene, which is associated with migraine with or without aura, susceptibility to. This suggests shared therapeutic mechanisms.

---

### Path #8: obsolete susceptibility to ischemic stroke

**Path:**
```
[Tezepelumab] --(0.874)--> [Chlorotrianisene] --(0.534)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 2 |
| Avg Attention | 0.7042 |
| Combined Score | 0.4979 |
| Confidence | ‚≠ê‚≠ê‚≠ê‚≠ê‚≠ê Very High |

**Node Types:** `drug` ‚Üí `drug` ‚Üí `disease`

**Interpretation:**

**Drug similarity path**: Tezepelumab is similar to Chlorotrianisene, which is associated with obsolete susceptibility to ischemic stroke. This suggests shared therapeutic mechanisms.

---

### Path #9: ovarian small cell carcinoma

**Path:**
```
[Tezepelumab] --(0.874)--> [Chlorotrianisene] --(0.534)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 2 |
| Avg Attention | 0.7041 |
| Combined Score | 0.4978 |
| Confidence | ‚≠ê‚≠ê‚≠ê‚≠ê‚≠ê Very High |

**Node Types:** `drug` ‚Üí `drug` ‚Üí `disease`

**Interpretation:**

**Drug similarity path**: Tezepelumab is similar to Chlorotrianisene, which is associated with ovarian small cell carcinoma. This suggests shared therapeutic mechanisms.

---

### Path #10: dementia (disease)

**Path:**
```
[Tezepelumab] --(0.874)--> [Chlorotrianisene] --(0.534)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 2 |
| Avg Attention | 0.7041 |
| Combined Score | 0.4978 |
| Confidence | ‚≠ê‚≠ê‚≠ê‚≠ê‚≠ê Very High |

**Node Types:** `drug` ‚Üí `drug` ‚Üí `disease`

**Interpretation:**

**Drug similarity path**: Tezepelumab is similar to Chlorotrianisene, which is associated with dementia (disease). This suggests shared therapeutic mechanisms.

---

### Path #11: myxedema

**Path:**
```
[Tezepelumab] --(0.874)--> [Chlorotrianisene] --(0.534)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 2 |
| Avg Attention | 0.7038 |
| Combined Score | 0.4977 |
| Confidence | ‚≠ê‚≠ê‚≠ê‚≠ê‚≠ê Very High |

**Node Types:** `drug` ‚Üí `drug` ‚Üí `disease`

**Interpretation:**

**Drug similarity path**: Tezepelumab is similar to Chlorotrianisene, which is associated with myxedema. This suggests shared therapeutic mechanisms.

---

### Path #12: malignant sex cord stromal tumor of ovary

**Path:**
```
[Tezepelumab] --(0.874)--> [Chlorotrianisene] --(0.533)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 2 |
| Avg Attention | 0.7036 |
| Combined Score | 0.4976 |
| Confidence | ‚≠ê‚≠ê‚≠ê‚≠ê‚≠ê Very High |

**Node Types:** `drug` ‚Üí `drug` ‚Üí `disease`

**Interpretation:**

**Drug similarity path**: Tezepelumab is similar to Chlorotrianisene, which is associated with malignant sex cord stromal tumor of ovary. This suggests shared therapeutic mechanisms.

---

### Path #13: phosphorus metabolism disease

**Path:**
```
[Tezepelumab] --(0.874)--> [Chlorotrianisene] --(0.533)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 2 |
| Avg Attention | 0.7036 |
| Combined Score | 0.4975 |
| Confidence | ‚≠ê‚≠ê‚≠ê‚≠ê‚≠ê Very High |

**Node Types:** `drug` ‚Üí `drug` ‚Üí `disease`

**Interpretation:**

**Drug similarity path**: Tezepelumab is similar to Chlorotrianisene, which is associated with phosphorus metabolism disease. This suggests shared therapeutic mechanisms.

---

### Path #14: systemic lupus erythematosus (disease)

**Path:**
```
[Tezepelumab] --(0.874)--> [Chlorotrianisene] --(0.532)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 2 |
| Avg Attention | 0.7032 |
| Combined Score | 0.4972 |
| Confidence | ‚≠ê‚≠ê‚≠ê‚≠ê‚≠ê Very High |

**Node Types:** `drug` ‚Üí `drug` ‚Üí `disease`

**Interpretation:**

**Drug similarity path**: Tezepelumab is similar to Chlorotrianisene, which is associated with systemic lupus erythematosus (disease). This suggests shared therapeutic mechanisms.

---

### Path #15: theca steroid-producing cell malignant tumor of ovary, not further specified

**Path:**
```
[Tezepelumab] --(0.874)--> [Chlorotrianisene] --(0.532)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 2 |
| Avg Attention | 0.7028 |
| Combined Score | 0.4970 |
| Confidence | ‚≠ê‚≠ê‚≠ê‚≠ê‚≠ê Very High |

**Node Types:** `drug` ‚Üí `drug` ‚Üí `disease`

**Interpretation:**

**Drug similarity path**: Tezepelumab is similar to Chlorotrianisene, which is associated with theca steroid-producing cell malignant tumor of ovary, not further specified. This suggests shared therapeutic mechanisms.

---

### Path #16: malignant germ cell tumor of ovary

**Path:**
```
[Tezepelumab] --(0.874)--> [Chlorotrianisene] --(0.529)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 2 |
| Avg Attention | 0.7015 |
| Combined Score | 0.4960 |
| Confidence | ‚≠ê‚≠ê‚≠ê‚≠ê‚≠ê Very High |

**Node Types:** `drug` ‚Üí `drug` ‚Üí `disease`

**Interpretation:**

**Drug similarity path**: Tezepelumab is similar to Chlorotrianisene, which is associated with malignant germ cell tumor of ovary. This suggests shared therapeutic mechanisms.

---

### Path #17: coronary artery disease

**Path:**
```
[Tezepelumab] --(0.874)--> [Chlorotrianisene] --(0.529)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 2 |
| Avg Attention | 0.7014 |
| Combined Score | 0.4959 |
| Confidence | ‚≠ê‚≠ê‚≠ê‚≠ê‚≠ê Very High |

**Node Types:** `drug` ‚Üí `drug` ‚Üí `disease`

**Interpretation:**

**Drug similarity path**: Tezepelumab is similar to Chlorotrianisene, which is associated with coronary artery disease. This suggests shared therapeutic mechanisms.

---

### Path #18: myofibroma

**Path:**
```
[Tezepelumab] --(0.874)--> [Chlorotrianisene] --(0.528)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 2 |
| Avg Attention | 0.7010 |
| Combined Score | 0.4957 |
| Confidence | ‚≠ê‚≠ê‚≠ê‚≠ê‚≠ê Very High |

**Node Types:** `drug` ‚Üí `drug` ‚Üí `disease`

**Interpretation:**

**Drug similarity path**: Tezepelumab is similar to Chlorotrianisene, which is associated with myofibroma. This suggests shared therapeutic mechanisms.

---

### Path #19: stroke disorder

**Path:**
```
[Tezepelumab] --(0.874)--> [Chlorotrianisene] --(0.527)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 2 |
| Avg Attention | 0.7006 |
| Combined Score | 0.4954 |
| Confidence | ‚≠ê‚≠ê‚≠ê‚≠ê‚≠ê Very High |

**Node Types:** `drug` ‚Üí `drug` ‚Üí `disease`

**Interpretation:**

**Drug similarity path**: Tezepelumab is similar to Chlorotrianisene, which is associated with stroke disorder. This suggests shared therapeutic mechanisms.

---

### Path #20: hepatic porphyria

**Path:**
```
[Tezepelumab] --(0.874)--> [Chlorotrianisene] --(0.527)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 2 |
| Avg Attention | 0.7005 |
| Combined Score | 0.4953 |
| Confidence | ‚≠ê‚≠ê‚≠ê‚≠ê‚≠ê Very High |

**Node Types:** `drug` ‚Üí `drug` ‚Üí `disease`

**Interpretation:**

**Drug similarity path**: Tezepelumab is similar to Chlorotrianisene, which is associated with hepatic porphyria. This suggests shared therapeutic mechanisms.

---

## 5. Interpretation Guidelines

### Attention Score Scale

| Score Range | Confidence | Interpretation |
|-------------|------------|----------------|
| ‚â• 0.70 | ‚≠ê‚≠ê‚≠ê‚≠ê‚≠ê Very High | Strong biological relationship |
| 0.60 - 0.70 | ‚≠ê‚≠ê‚≠ê‚≠ê High | Good evidence for connection |
| 0.50 - 0.60 | ‚≠ê‚≠ê‚≠ê Medium | Moderate support |
| 0.40 - 0.50 | ‚≠ê‚≠ê Low | Weak connection |
| < 0.40 | ‚≠ê Very Low | Speculative |

### How to Use This Report

1. **Prioritize high-scoring paths**: Focus on paths with combined scores > 0.45
2. **Validate intermediate nodes**: Cross-reference proteins/drugs with literature
3. **Consider path length**: Shorter paths (2-3 hops) are generally more reliable
4. **Check for known associations**: Some paths may represent known indications

---

*Report generated by TxGNN Path Analysis Pipeline*